KDC-MN-160 – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

DHEA is the most abundant circulating steroid hormone, produced by the adrenal glands. Levels decline with age. It serves as a precursor to both testosterone and estrogen. Sold as a supplement with mixed evidence for benefit in healthy adults. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Mature endogenous steroid with mixed clinical record and limited frontier research value

Look, DHEA is one of the most studied endogenous steroids on the planet, and thats kind of the problem. The literature is enormous, the compound has been an OTC supplement in the United States since the 1990s, and after thirty-plus years of serious clinical investigation the picture is underwhelming. Mixed results across virtually every indication: cognitive function in aging adults, depression, sexual function, bone density, body composition. The adrenal insufficiency angle is the most defensible, but even there the effect sizes are modest and the patient population is narrow enough that generalizability is a real concern.

The mechanism is more layered than most people credit. DHEA isn’t only an androgen/estrogen precursor. It’s also a sigma-1 receptor ligand and a positive allosteric modulator at NMDA receptors, which places it in the neurosteroid conversation alongside compounds like allopregnanolone and pregnenolone. That angle is genuine and underappreciated. But here’s the problem: if you’re running neurosteroid biology, you have cleaner probes. Sigma-1 work has more selective ligands. NMDA modulation has better characterized tools. DHEA does several things at once, none of them with the selectivity that makes a clean research question possible. The multi-target profile reads as messy rather than elegant.

The age-related decline narrative is compelling on its face. Circulating DHEAS peaks in the mid-20s and reaches 10 to 20 percent of that level by age 70. Thats a dramatic and highly reproducible fall. But replacement studies haven’t consistently reversed the endpoints that decline is supposed to explain. The working hypothesis now in serious aging research is that physiological DHEA decline may be partly a consequence of aging rather than a primary driver, and that systemic oral replacement doesn’t recapitulate the local paracrine production that matters at the tissue level. That reframe, if correct, makes the classic intervention paradigm less compelling.

Differentiation is another weak point. For hormone restoration in the clinic, direct testosterone or estrogen replacement is better characterized and clinically superior on relevant endpoints. For neurosteroid mechanism work, more selective compounds exist. DHEA occupies an uncomfortable middle ground: too mainstream and over-investigated to feel like frontier research, not specific enough mechanistically to serve as a clean probe tool.

We think the honest framing is that DHEA was a rational priority in the 1990s and 2000s, serious investigators did that work carefully, and the signal that emerged is real but modest and largely population-specific. As a reference standard for endogenous steroid panels or as a benchmark in age-related endocrine decline studies, it still earns a place in the lab. As a primary research question in 2025, the room is very crowded and the probability of a surprising new finding is low.

Novelty: 18
Mechanism promise: 38
In-category differentiation: 25
Evidence quality: 50
Translational signal: 38
Research bench value: 35

Rationale DHEA has a large, serious clinical literature but three decades of investigation have produced consistently modest and population-specific effects; novelty is minimal and differentiation is weak because more selective tools exist for each of its proposed mechanisms. Scored as established-mature, analogous to piracetam on the maturity axis.

Endogenous androgen precursor

An endogenous adrenal steroid hormone with androgenic and neurosteroid activity; declines with age and supplemented for hormone restoration.

Abstract

DHEA (dehydroepiandrosterone; CAS 53-43-0; molecular formula C19H28O2; molecular weight 288.42) is an endogenous adrenal steroid hormone produced by the adrenal cortex. DHEA and its sulfate (DHEAS) are the most abundant circulating steroid hormones in young adults; both decline progressively with age, reaching 10 to 20 percent of peak by age 70. The compound is a precursor for downstream androgen and estrogen synthesis and is also a sigma-1 receptor ligand and NMDA receptor PAM with neurosteroid activity. Supplementation has been studied for adrenal insufficiency, depression in older adults, sexual dysfunction, and cognitive function with mixed results. The compound is sold as a dietary supplement in the United States but is prescription-only or banned in many other jurisdictions. Doses are typically 25 to 100 mg per day; female subjects often require lower doses to avoid virilizing effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-160Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-160

DHEA (Dehydroepiandrosterone)

Abstract

Read the full monograph